An increasing number of new drug entities require solubilization technologies for efficacious use. This webinar reviews the use of multicomponent amorphous dispersion systems, in which two or more excipients are formulated with the API for bioavailability enhancement of the low-solubility compound. The use of amorphous spray-dried dispersion formulations is highlighted, including an overview of the formulation process, the physical state of formulation components, and rapid performance screening tests that are used to guide selection of formulation components. In addition, the design of multicomponent amorphous formulations is described. Case studies are presented that show how multicomponent amorphous compositions and architectures can be used to simultaneously achieve manufacturability, physical stability, rapid dissolution, and sustainment of supersaturated drug concentrations.
Please note that Lonza has updated its Privacy Policy. By visiting our website or using services provided by Lonza, you are accepting the practices described in the Privacy Policy.
We also use cookies on our websites. Cookies allow us to give you the best browsing experience and help us to understand how you use our site. You can disable cookies but parts of our website may not work. Please read our updated Cookies Policy for information about which cookies we use and the information we collect. By continuing to use this website, you agree that we may store and access cookies on your device.
By clicking "I Agree", you confirm that you are above the age of 16, that you have read and understood the Privacy Policy and the Cookies Policy, and that you agree to the collection, use and processing of your Personal Information by Lonza in accordance with said policies.